<SEC-DOCUMENT>0001628280-15-008089.txt : 20151030
<SEC-HEADER>0001628280-15-008089.hdr.sgml : 20151030
<ACCEPTANCE-DATETIME>20151030172626
ACCESSION NUMBER:		0001628280-15-008089
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20151030
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20151030
DATE AS OF CHANGE:		20151030

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		151188582

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a8kforcaldolorsafety103020.htm
<DESCRIPTION>8-K CALDOLOR SAFETY 102015
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>8-K</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s21fde49ba1f34b5480b4bddc4c912ec3"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;">FORM 8-K</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">CURRENT REPORT</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="51%"></td><td width="5%"></td><td width="44%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of Report (Date of Earliest Event Reported):</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October 30, 2015 (October 27, 2015)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;">Cumberland Pharmaceuticals Inc.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">__________________________________________</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td width="0%"></td><td width="33%"></td><td width="18%"></td><td width="5%"></td><td width="11%"></td><td width="33%"></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Tennessee</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">001-33637</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">62-1765329</font></div></td></tr><tr><td><font>&#160;</font></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or other jurisdiction of incorporation)</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission File Number)</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(I.R.S. Employer Identification No.)</font></div></td></tr><tr><td><font>&#160;</font></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2525 West End Avenue, Suite 950, Nashville, Tennessee</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37203</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Zip Code)</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registrant's telephone number, including area code:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(615) 255-0068</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">____________________________________________</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Former name or former address, if changed since last report</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s21fde49ba1f34b5480b4bddc4c912ec3"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.01 Other Events</font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 27, 2015, Cumberland Pharmaceuticals Inc. (the "Company") issued a press release announcing the publication of an integrated safety analysis that supports the safety of the Company's Caldolor</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">ibuprofen) </font><font style="font-family:inherit;font-size:10pt;">Injection product.  A copy of the press release is furnished as Exhibit 99.1.</font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s21fde49ba1f34b5480b4bddc4c912ec3"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="68%"></td><td width="32%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cumberland Pharmaceuticals Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">October 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">By: A.J. Kazimi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Name: A.J. Kazimi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Title: Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:15px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:384px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:384px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:384px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><hr></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit&#160;Index </font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.5625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="20%"></td><td width="13%"></td><td width="67%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press release dated October 27, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>prcaldolorsafety10272015-01.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s634867288fbf49ec824a72d3ea91325f"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:32px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:32px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">FOR IMMEDIATE RELEASE</font></div><div style="line-height:120%;padding-bottom:32px;padding-top:8px;text-align:center;"><img src="copyofcumberlandlogoa02.jpg" style="font-size:11pt;height:108px;width:474px;"></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NEW CALDOLOR INTEGRATED SAFETY ANALYSIS PUBLISHED</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SUPPORTING THE SAFETY OF CALDOLOR</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;(IBUPROFEN) INJECTION</font></div><div style="line-height:120%;padding-bottom:32px;padding-top:32px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">Caldolor demonstrates favorable safety profile with cumulative analysis of clinical data </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">NASHVILLE, Tenn. (Tuesday, October 27, 2015)</font><font style="font-family:inherit;font-size:11pt;">&#32;- Cumberland Pharmaceuticals Inc. </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">(NASDAQ: CPIX)</font><font style="font-family:inherit;font-size:11pt;">&#32;today announced the publication of an integrated safety analysis adding to the growing body of literature that support the safety of Caldolor</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;(</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">ibuprofen</font><font style="font-family:inherit;font-size:11pt;">) Injection.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;</font><font style="font-family:inherit;font-size:11pt;">The data in this cumulative safety analysis is derived from ten sponsored clinical studies investigating intravenous ibuprofen for the treatment of pain and/or fever in adult patients.  Over 1,750 adult patients have been included in safety and efficacy trials over eleven years. The new publication is currently available as open access articles in the </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Journal of Pain Research</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:120%;padding-bottom:32px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"This ongoing surveillance and analysis continues to validate the impressive efficacy and safety results of intravenous ibuprofen administration in the perioperative patient that we have been observing since 2007 in our research patients, and since 2009 in our clinical patients," states Stephen R. Southworth, MD, lead author and researcher from North Mississippi Sports Medicine and Orthopedic Clinic. </font></div><div style="line-height:120%;padding-bottom:32px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The incidence of adverse events, changes in vital signs and clinically significant laboratory parameters were summarized and compared to patients receiving placebo or active comparator drug. Patients receiving Caldolor required less morphine and experienced fewer adverse events relative to those who received placebo with morphine rescue. Results from the integrated analysis continue to demonstrate the safety of Caldolor, supporting its use in hospitalized patients.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">About Caldolor </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Caldolor is indicated for the management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics, and for the reduction of fever in adults. It was the first FDA approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with asthma, urticaria, or allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. Caldolor should be used with caution in patients with prior history of ulcer disease or GI bleeding, in patients with fluid retention or heart failure, in the elderly, those with renal impairment, heart failure, liver impairment, and those taking diuretics or ACE inhibitors. Blood pressure should be monitored during treatment with Caldolor. For full prescribing information, including boxed warning, visit </font><font style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">www.caldolor.com</font><font style="font-family:inherit;font-size:11pt;">. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">About Cumberland Pharmaceuticals</font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s634867288fbf49ec824a72d3ea91325f"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's marketed products include Acetadote</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;(</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">acetylcysteine</font><font style="font-family:inherit;font-size:11pt;">) Injection for the treatment of acetaminophen poisoning, Caldolor</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;(</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">ibuprofen</font><font style="font-family:inherit;font-size:11pt;">) Injection, the first injectable treatment for pain and fever approved in the United States, Kristalose</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;(</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">lactulose</font><font style="font-family:inherit;font-size:11pt;">) for Oral Solution, a prescription laxative, Vaprisol</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;(</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">conivaptan</font><font style="font-family:inherit;font-size:11pt;">) Injection, for the treatment of hyponatremia and Omeclamox-Pak</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;for the treatment of </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">H. pylori</font><font style="font-family:inherit;font-size:11pt;">&#32;and duodenal ulcer disease.&#160; Cumberland is dedicated to providing innovative products that improve quality of care for patients.&#160; For more information on Cumberland Pharmaceuticals Inc., please visit </font><font style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">www.cumberlandpharma.com</font><font style="font-family:inherit;font-size:11pt;">. </font></div><div style="line-height:174%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;padding-bottom:13px;padding-top:8px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">-###-</font></div><div style="line-height:174%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Investor Contact:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Media Contact:</font></div><div style="line-height:174%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Erin Smith</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Rebecca Kirkham</font></div><div style="line-height:174%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Corporate Relations</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Lovell Communications</font></div><div style="line-height:174%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(615) 255-0068</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">(615) 297-7766</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>copyofcumberlandlogoa02.jpg
<TEXT>
begin 644 copyofcumberlandlogoa02.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !: 8P# 2(  A$! Q$!_\0
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MQI5+7WDVM6_R79"J0DXJ53>\?S/T _X*C_\ *,_]HK_LF/B3_P!-5S7XQ_\
M!'7QA^W?H/[(,EO^S+X4^&>L_#K_ (2&]>:X\020K>_V@5C^T+\]S'\@^3;\
MM?L__P %.+*;4O\ @FU^T%:V\,MQ<W/PV\10Q0Q(99)';2[D*JJ.22:_%?\
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M_E.BE[;Z;9$_NHE?G#\2OV=?'_[.%WY'COP9KGAA$?;]LFM_/TY_I=1[H/\
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MI;=XUV[8)=/;YC*6K)4FX.?]6ZOY#<M;'U;117Y+ZK^V/:Z=\>_C<WQ*^/\
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M?@_XR\6:O?>(/$7B'0EN;[4;T)]HNW\V1=S[%"YP!TJI82<:3JRTL[6Z]?\
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M)A:5"C"<92E.UO)[72_4)2DGHKGZ#T45\P?LE?%_Q/XZ_;V_:P\,ZQK5U?\
MA_P1KWARTT"Q<)Y>FQW'AZSNIU3 S\\TKN=Q/7BHA2<XRDOLJ[^]+]1N232?
M4^GZ*\<_;O\ VH8?V+/V0?B#\4I]-DU@^#-'EO8+!7\H7MQPD,;/_P LT:5T
MW/\ P+ENU>:Z7_P3]\>>,M/@UGQU^TG\9Y?&[_OWF\(WUGH.B:;)NW&*UT[[
M/)')"OW1]N^U2,!\SFG3I)Q]I-VCLMW=Z=O4')WLCZMHKE/A#X:U_P %_##0
M])\5>)G\9^(M.L8H-1UU[&.P;5IU7#W!MXOW<6X\[4^4=J\__;M_:>NOV5_@
M)-JN@Z;!X@\>^([^V\,>"M$ED55UK7+QO*M87RZ?N4^:>9@V4M[>>3^"LXQ<
MI\D=1MZ7/:Z*^4OV&?B5XU^%GQ?\5_L]_%CQ1?>-_&7A:QA\3^&/&%[90V4W
MC;0KAO+ED>*%B@N+&\WVTN @\J2QDQF<U]6TYPY7847<**^:O^"=?Q2\2_%2
MQ^-K>)-;OM:;P_\ %OQ%H6F?:4C7[#8P21B&W38%^1 QQN^:OI6JK4G3FX2Z
M!&2DKH**_/;]MKQUXE\/_M@^*1\9/%_QS^'/P&L-!LKCP7K/PQL+Q].^T ,-
M1FUNZL;:>Y@F622$1+-Y=GY*%OGDW[?KW]DO5-.UG]GWPS=:1\2[GXPZ7<P/
M+:>+YY[&>3686F?8S/9116[E!B+<D:_ZKYOGW&KJX?DIQJ7O?UM]^U^_82G>
M5CTRBBBN<L**** "HY8EFC9&7<K_ "E3TQ4E% 'EOC#]BWX2>/+AY]4^&W@J
MYN7^9IUTF&*9_K(BAJ_(#_@L[\;?''[!W[?NC?#_ ."OC/Q#\+_!FI^!]/U^
M[T?09UB@NM0FO]1MY+AMZN=[0VL"<'_ED*_=&OP(_P"#EBY6W_X*O^%"_P#'
M\,M)BC7!9I)&U?6 JJH^\Q/05]'PM1A4QZ51)KEEHU<X<PDU2T?5&W^SU^TU
M\4?B!>VRZ]\4/B/JJO\ ZR.7Q)>(K_[R12*E?HK^S'X?T_\ X0O4KIK"QFO?
MLW_'Q+&LMQS_ +;Y?]:^%_V-/^">WQQUFPL]1?X::YH]D_W9-=GM]+E_X%!)
M)]H7_@<5?I9\$OV6O$WA;PU)9Z]K6G:3'<+LFAT7=<3R+_=%S,B[!_NQ;_22
MNG/*U!>[2E'?I;]#3#WM=GRI\7OAKXA^./Q(_P"$5\*V?]JZ]>?>\W<EKIL9
M_P"7BZ=<^7&/^^W^ZBLU?:'['W[)'AW]D+X5+H.B^;=7U],+[6-5F0+/J]X5
M56F8?P+A=J)T1,+ZFN]\!_#_ $GX:Z"FEZ/80V-J':9@FYGFD;[TDCMEY)#W
M=B6:NAKP<3CYU::I1T@NG=]V;J"O<*\:^*G[*Z?$W]KWX2?%=M;FL7^%6FZ]
M8+IJVJNFJ#58[1&9I-P,?E_8P>%.[?VKV6BN2$Y0=X]FODU9_@4U?<*\Y_:J
M^" _:9_9A^(_PW_M+^Q5^(/A?4_#37X@^T?8?MMK);F;R]R[RGF[MNY=V.HK
MT:BI3:=T,X#5O@R-4_9ON?A[_:,JK<^&V\._;Q"NY,VOV?SMF['^UMS4G[.'
MPC7X ?L^>!? :WTNJKX)\/V&@+>O"(FO%MK>. 2E!D(6V9QVKNZ*;G)KE>U[
MD\JO?Y'SU^T!^P'X7_:R_:'T+Q;\36LO&?@WPEH5QI^C>"M1TV.738-1NI/]
M)U24LQ\Z;R$B@B5EQ"#<,I+3?)RNO_\ !)KX9>$O&W@7Q;\'-$\/?!3QOX&\
M01:K'J^@:#;,FJV+CRK_ $NZB^7S+>YMF=/O*T4OE3)\T?/U?16L<56C'DC)
MI=NGW;"]G&][:]^H5\U>$O\ @FUX2C^'GQW\(>+[N7QAX:^.WC6[\97UL\'V
M-]*DFM[&*.."1&+>9!)8Q31SKL=)-C##(&KZ5HJ(59Q347:_Z#<;G!_L_P#@
M;Q-\,/@_H'A_Q;XPF\?>(='MC;W7B&:P6QFU4!F\N26)&9/-\O8'9?ON"^U-
MVP8'QH_9I3XP_'7X.>.3K#V,GPDUK4=62S6 2+J1N]*N].,9?</+V_:B_P#%
MDIBO6Z*F,Y*3DM]?QT?X!RZ6/GKX!_L"Z#\ /VI_B%\3;'7-;U%/&+2OI6A7
M<[26/A!KR9+K5_L2ECL&H7L4-U/_ --8AC%='^PA^RM%^Q#^R1X$^%$.M2>(
MX?!&F_V>FIR6JVKW?SL^XQ!F"?>_O&O8J*N5>I*+C)Z.WX)I?@V"BD>$?M1?
ML6:=^UW\3_ 4WC;4+?5OAOX)>[U*Z\$W.DQW%GX@U22+R+6ZNI7)S':QO<F.
M%5QYTL<I;,$8KSSXF?\ !'KX1_V)INI?"3PSX5^"7Q(\,ZK;:UX=\8^'M%5+
MK3;B)BLD<D<3Q?:;:XMWGMYK>1]DD<YS\RH5^NJ*N&+K0CR1DTNW3YK9_,4J
M<9.[05\U>+OV&?$/@?XW^(_B'\$_B/\ \*UU7QS=QZAXK\/ZMH?_  D/A77;
MR.#R/M_V)9[:>VO&C6)9);:ZB6;R(_-CD?YZ^E:*RA4E!W7^?YE-'D?[/_PE
M^)/@SQ+K6M_$?XIQ^.+W5 L-GI>D^&X]!T+1XD_BA@:6ZNGF<_?>:[D7IM1.
M=W4_'3X8P_''X)^,/!4]W)81>,-%O=%DN8D#/ MQ \+2*IZE0]=G11[27,I]
M1<JM8^4/A3^RA^T7\*O!OA7PY:_M"^";G1_#-I9Z<D<GPM*S3VULL<94N-4P
MKNB?>"X&?NU]7T45=:O.J[SM\DEOZ)"A!15D?-7CO]BOQCX<_:?\2?%?X/?$
M?3? >L^/[.TM_&&C>(O#3^(]"UV:TC\FUOHXH[RSN+:[2#$+,EQY4L:1;HMZ
M;ZZ']D7]CZ;]G+7?&_BWQ+XKN?B#\3OB??6][XG\0R6$>G02):PB"TL[2TC+
M"WM((]VQ&>60M+*[RR,]>Z45+K5''EOV7G9>>Y7*@KR+X*?LR?\ "G/C[\9?
M'::U)J+_ !=UG3M6:Q:U\I-*^R:3::=L#[CYF\6OF9PN-^WG&ZO7:*E2:32Z
M_P##@TF%>-_!#]E:/X+_ +2_QK^(@UJ34'^,6I:5J+V#6HC72OL.EP6 59-Q
M\SS/($AX7;G%>R441FXII==']]_S06U3.9^*_P +]$^-OPTU_P (>)].AU;P
MUXITZ;2M4LI"RK=6TZ-'+&2"" 48@XYKY]T+]E;]H7X:^&IO#7A7]I'3-1T"
M&*.UT^_\;^ /^$@\3V,21JGS7\&H6<%RXVY\VXM)9&/^M:4Y-?5%%53JRAHK
M6\TG^:8.*>YR7P@\!WWPT^'VGZ)J7BG7_&M]8JWG:WK(MA?WS%V?=(MM%%$/
MO8 2-1M KR#X\_\ !/OPY^U3^TUI/C#XG7,/CCP1X:T&33=!\":AI<,FE6.H
MW$G^E:K*S9:>=H%B@B#?+ GG[?FF)'T911"K.$N>#L^X-)JS/E:__P""4'PN
M\#?$/X?^,?A%H.@?!GQ9X&\01ZD]_P"'M%MT76M.D4PW^E74?R[X+B!CM;.Z
M&:."9<^7M;ZIHHHJ5JE36I)M]WO]XHQ4=$?(/A;]A3XS_!WQ3\09OAQ\=?#/
MA[1?'GBS4?%YL=6^'0U::PGO2K/'YRZA#YB*R_+E,U]4^%[._P!.\/V5OJ=[
M%?ZA#;HES=16_D)=2A?GD6/<VS<W.W<V*U:*NMB)U?CM]R7;LE?84(*.QX;\
M5_@_\<;_ .)FJZS\/_C7H.A:#K%I%$- \5> 8]>M]&F1=IFL9;6\L)QYGWG6
M[>Z^?[GEI\E;_P"R1^S9;?LF_ ^Q\'0ZWJ'B2>.^O]7U'5KV"&"74M0O[R>^
MO+CRH$2&%'N+B4K%$BHBD+[UZG16;J2<>3IZ(KE04445 PHHHH **** "OG3
M_AB/1O$?_!2/4/CYK^EV6H:KH_@G3?"'A9YD65M-*W>H7%[=(K9V2NMU!"L@
M 94$JAMLKBOHNBKA4E&_*[75OD2XI[A1114%!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
80 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
